CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 288 enrolled
Drug / intervention
OROS hydromorphone HCl +1 moredrug
Likely dose
OROS hydromorphone HCl 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00980798
NCT00980798Phase 3Completed

Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Investigate the Analgesic Effect of OROS Hydromorphone Hydrochloride in Comparison With Placebo in Subjects With Moderate to Severe Pain Induced by Osteoarthritis of the Hip or the Knee

Janssen-Cilag International NV·interventional·Posted Sep 21, 2009·Updated Apr 25, 2014

In Brief

A Phase 3 clinical trial evaluating OROS hydromorphone HCl and Placebo for Pain and 2 related conditions. Completed, enrolled 288 participants across 12 sites in 4 countries.

Detailed Summary

This clinical trial tests the pain relieving effectiveness of OROS hydromorphone, a once-daily formulation of a strong opioid against placebo in patients, who are suffering from pain due to osteoarthritis of the hip or the knee and who previously did not receive any strong opioids.The clinical trial tests the effect of the treatment on symptoms of pain, stiffness and physical function. The effect of the treatment on parameters on health related quality of life as well as quality of sleep will be measured.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCzechia, Romania, Slovakia, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2009
Enrollment StartOct 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 16.8 years ago

Interventions

OROS hydromorphone HCldrug

4 to 32 mg taken orally once daily for 16 weeks

Placebodrug

placebo tablet once daily for 16 weeks